Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 18, 2024 (filed on Apr 19, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:14,164Price:--
-
Apr 18, 2024 (filed on Apr 19, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-14,164Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Dunlop A. SinclairOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,500Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Dunlop A. SinclairOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:1,500Price:$13.19
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-69,107Price:--
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,728Price:$54.92
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-64,379Price:$54.12
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:69,107Price:$3.76
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,000Price:--
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,000Price:$58.66
Filings by filing date
-
Apr 18, 2024 (filed on Apr 19, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:14,164Price:--
-
Apr 18, 2024 (filed on Apr 19, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-14,164Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Dunlop A. SinclairOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-1,500Price:--
-
Apr 12, 2024 (filed on Apr 15, 2024)Insider Name:Dunlop A. SinclairOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:1,500Price:$13.19
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-69,107Price:--
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,728Price:$54.92
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-64,379Price:$54.12
-
Apr 08, 2024 (filed on Apr 09, 2024)Insider Name:Deschatelets PascalOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:69,107Price:$3.76
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-4,000Price:--
-
Apr 01, 2024 (filed on Apr 02, 2024)Insider Name:Sullivan Timothy EugeneOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,000Price:$58.66
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 100 Fifth Avenue WALTHAM MA 02451 |
Tel: | 1-617-5998178 |
Website: | https://apellis.com |
IR: | See website |
Key People | ||
Cedric Francois President, Chief Executive Officer, Co-Founder, Director | Mark Delong Chief Business and Strategy Officer | Pascal Deschatelets Co-Founder, Chief Scientific Officer |
Timothy Sullivan Chief Financial Officer, Treasurer | Nur Nicholson Chief Technical Operations Officer | Adam J. Townsend Chief Operating Officer |
Karen Lewis Chief People Officer | James G. Chopas Chief Accounting Officer, Vice President, Corporate Controller | David O. Watson General Counsel | Caroline Baumal Chief Medical Officer |
Business Overview |
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company's approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan), is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and United Kingdom. |
Financial Overview |
For the fiscal year ended 31 December 2023, Apellis Pharmaceuticals Inc revenues increased from $75.4M to $396.6M. Net loss decreased 19% to $528.6M. Revenues reflect Product revenue, net increase from $65.1M to $366.3M, Licensing and other revenue increase from $10.3M to $30.3M. Lower net loss reflects Research and Development - Balancing va decrease of 23% to $146.2M (expense), Loss on conversion of debt decrease from $32.9M (expense) to |
Employees: | 702 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5,932M as of Dec 31, 2023 |
Annual revenue (TTM): | $396.59M as of Dec 31, 2023 |
EBITDA (TTM): | -$515.34M as of Dec 31, 2023 |
Net annual income (TTM): | -$528.63M as of Dec 31, 2023 |
Free cash flow (TTM): | -$595.51M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $57.50M as of Dec 31, 2023 |
Shares outstanding: | 120,581,749 as of Feb 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |